Cargando…

S211: EFFICACY AND SAFETY OF ROPEGINTERFERON ALFA-2B FOR PRE-FIBROTIC PRIMARY MYELOFIBROSIS AND DIPSS LOW/INTERMEDIATE-1 RISK MYELOFIBROSIS: UPDATED RESULTS AND GENOMIC CHARACTERISTICS

Detalles Bibliográficos
Autores principales:	Gill, Harry, Au, Lester, Tsai, Dorothy, Leung, Man Kit Garret, Yim, Rita, Chin, Lynn, LI, Vivian, Lee, Paul, Sin, Chung Fung Albert, Hou, Hsin-An, Chen, Chih-Cheng, Kwong, Yok Lam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428496/ http://dx.doi.org/10.1097/01.HS9.0000967756.92473.72

Ejemplares similares

Use of ropeginterferon in inducing graft versus myelofibrosis effect in post‐transplant myelofibrosis relapse
por: Srivastava, Barnali, et al.
Publicado: (2023)

Nationwide prospective survey of secondary myelofibrosis in Japan: superiority of DIPSS-plus to MYSEC-PM as a survival risk model
por: Shide, Kotaro, et al.
Publicado: (2023)

S133: AN ENTIRELY ORAL REGIMEN OF ORAL-ATO, ATRA AND ASCORBIC ACID IN RISK-ADAPTED TREATMENT OF NEWLY-DIAGNOSED APL RESULTED IN EXCELLENT CLINICAL/MOLECULAR RESPONSES WITH DURABLE REMISSION
por: Gill, Harry, et al.
Publicado: (2023)

GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes
por: Manshouri, Taghi, et al.
Publicado: (2022)

Myelofibrosis
por: Passamonti, Francesco, et al.
Publicado: (2023)

S212: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS
por: Zhang, Yi, et al.
Publicado: (2023)

Diabetes and Second Neoplasia Impact on Prognosis in Pre-Fibrotic Primary Myelofibrosis
por: Cattaneo, Daniele, et al.
Publicado: (2022)

Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups
por: Gisslinger, Heinz, et al.
Publicado: (2020)

P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA
por: Xu, Z., et al.
Publicado: (2022)

PB2060: THE MDS-SPECIFIC COMORBIDITY INDEX (MDS-CI) PREDICTS SURVIVAL INDEPENDENTLY FROM DIPSS AND MIPSS70 IN PATIENTS WITH OVERT MYELOFIBROSIS NOT ELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION.
por: Koster, K.-L., et al.
Publicado: (2022)

Real-life ruxolitinib experience in intermediate-risk myelofibrosis
por: Arikan, Fatma, et al.
Publicado: (2021)

Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013)

Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera
por: Gerds, Aaron T, et al.
Publicado: (2023)

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b
por: Kiladjian, Jean-Jacques, et al.
Publicado: (2022)

A Case Report of Ropeginterferon Alfa-2b for Polycythemia Vera during Pregnancy
por: Bang, Su-Yeon, et al.
Publicado: (2023)

Murine Models of Myelofibrosis
por: Jacquelin, Sebastien, et al.
Publicado: (2020)

Fibrocytes in primary myelofibrosis
por: Shimoda, Kazuya, et al.
Publicado: (2021)

The Role of Navitoclax in Myelofibrosis
por: Pandravada, Sasirekha, et al.
Publicado: (2021)

Osteolytic lesions in myelofibrosis
por: Johnson, Isla, et al.
Publicado: (2021)

The odyssey of pacritinib in myelofibrosis
por: Venugopal, Sangeetha, et al.
Publicado: (2022)

Novel therapeutics for myelofibrosis
por: Lee, Sung-Eun
Publicado: (2023)

S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY
por: Ayala, Rosa, et al.
Publicado: (2023)

S205: INHIBITING THE ALARMIN-DRIVEN HEMATOPOIESIS-STROMAL CELLS CROSSTALK IN PRIMARY MYELOFIBROSIS AMELIORATES BONE MARROW FIBROSIS
por: Gleitz, Hélène, et al.
Publicado: (2023)

Captopril mitigates splenomegaly and myelofibrosis in the Gata1 (low) murine model of myelofibrosis
por: Corey, Seth J., et al.
Publicado: (2018)

Circulating megakaryocyte in primary myelofibrosis: an uncommon finding in a myelofibrosis blood smear
por: Cantó, Pedro Asensi, et al.
Publicado: (2021)

Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
por: Mosquera-Orgueira, Adrián, et al.
Publicado: (2022)

Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data
por: Schalling, Martin, et al.
Publicado: (2017)

PB2039: CLINICAL FEATURES AND NEXT-GENERATION SEQUENCING LANDSCAPE OF ESSENTIAL THROM-BOCYTHEMIA，PREFIBROTIC PRIMARY MYELOFIBROSIS, AND OVERT FIBROTIC PRIMARY MYELOFIBROSIS: A CHINESE RETROSPECTIVE STUDY
por: Huang, J., et al.
Publicado: (2022)

PB2211: DIFFERENCES IN POST-POLYCYTHEMIA VERA AND POST–ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS VS PRIMARY MYELOFIBROSIS IN FIBROTIC STAGE: A RETROSPECTIVE, REAL-WORLD STUDY CONDUCTED IN CHINA
por: Wang, Shengjie, et al.
Publicado: (2023)

Immunomodulatory and direct activities of ropeginterferon alfa‐2b on cancer cells in mouse models of leukemia
por: Sakatoku, Kazuki, et al.
Publicado: (2022)

S167: EFFICACY AND SAFETY OF LUSPATERCEPT FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH MYELOFIBROSIS: RESULTS FROM THE ACE-536-MF-001 STUDY
por: Gerds, Aaron T., et al.
Publicado: (2023)

Splenic Marginal Zone Lymphoma with Prominent Myelofibrosis Mimicking Triple-Negative Primary Myelofibrosis
por: Tsutsui, Miyuki, et al.
Publicado: (2019)

The Sarawak Myelofibrosis (SaMy) experience: Demographics and outcome of myelofibrosis patients in Sarawak, Malaysia
por: Tang, Andy Sing Ong, et al.
Publicado: (2023)

Myelofibrosis and the biology of connective tissue
por: Geary, G.
Publicado: (1985)

Factors affecting prognosis in myelofibrosis
por: Onida, Francesco
Publicado: (2009)

The evolving treatment paradigm in myelofibrosis
por: Mesa, Ruben A.
Publicado: (2013)

Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)

Myelofibrosis Treatment Algorithm 2018
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Chronic Lymphocytic Leukemia and Myelofibrosis
por: Darawshy, Fares, et al.
Publicado: (2018)

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
por: Manduzio, Palma
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9cdj1mqonssuun8qbbenojvf2l